Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-27EMA Authorised: Briviact (in Italy: Nubriveo) (Brivaracetam) — UCB Pharma SA
The EMA lists Briviact (brivaracetam) as authorised in Italy under the brand Nubriveo for epilepsy, with UCB Pharma SA as the marketing auth…
-
CLINICAL_TRIALS trial_result · 2026-01-26Clinical Trial Update: Evaluating the Role of Inflammation in Neonatal Epileptogenesis
A completed clinical trial conducted by the University of California, San Francisco evaluating how inflammation may contribute to epileptoge…
-
EMA approval · 2026-01-26EMA Authorised: Levetiracetam Actavis (levetiracetam) — Actavis Group PTC ehf
The European Medicines Agency has authorised Levetiracetam Actavis, a generic levetiracetam product, for use in epilepsy.
-
EMA approval · 2026-01-26EMA Authorised: Levetiracetam Teva (levetiracetam) — Teva B.V.
EMA has authorised Levetiracetam Teva (levetiracetam) for the treatment of epilepsy. The marketing authorization holder is Teva B.V., with d…
-
EMA approval · 2026-01-26EMA Authorised: Levetiracetam ratiopharm (levetiracetam) — ratiopharm GmbH
The EMA has authorised a generic levetiracetam product (Levetiracetam ratiopharm) by ratiopharm GmbH for epilepsy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-26EMA Authorised: Levetiracetam Actavis Group (levetiracetam) — Actavis Group PTC ehf
EU marketing authorisation granted for Actavis Group PTC ehf's generic levetiracetam for epilepsy.
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures [Phase 2]
A Phase 2 long-term study of RAP-219 for safety and effectiveness in adults with focal onset seizures is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-23Clinical Trial Update: Tianasen (ASO-GNAO1) for GNAO1-Encephalopathy With Epilepsy and Movement Disorders. [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating Tianasen (ASO-GNAO1) for GNAO1-related encephalopathy presenting with epilepsy and movement disorders; c…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study [Phase 2]
Phase 2 trial investigating sirolimus for preventing onset and progression of epilepsy in tuberous sclerosis complex; currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Cannabidiol for Pediatric Epilepsy (Compassionate Use)
Cannabidiol was used under a compassionate-use program for children with refractory epilepsy, but the trial NCT02556008 is no longer availab…
-
EMA approval · 2026-01-21EMA Authorised: Lacosamide Adroiq (lacosamide) — Extrovis EU Ltd
The European Medicines Agency authorised Lacosamide Adroiq for the treatment of epilepsy, with Extrovis EU Ltd as the marketing authorizatio…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Low-Intensity Focused Ultrasound Neuromodulation for Epilepsy [NA]
Enrollment-by-invitation is ongoing for a study evaluating low-intensity focused ultrasound neuromodulation as a treatment for epilepsy.
-
FDA approval · 2026-01-21FDA Approved: LACOSAMIDE — Original Application (GLENMARK PHARMACEUTICALS INC., USA)
FDA approved Glenmark Pharmaceuticals' lacosamide original application, authorizing a generic lacosamide product. Lacosamide is used for the…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Evaluation of the Efficacy of Neurofeedback Technique Based on EEG Desynchronization in Epileptic Patients [NA]
A clinical trial is evaluating the efficacy of an EEG desynchronization-based neurofeedback technique in epilepsy patients, including those …
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Evaluation of the Risk of Cognitive Deficit After Surgery of Epilepsy by Dynamic Spectral Imaging (ISD) of the Cognitive Functions in Patients Explored in StereoElectroEncephaloGraphy (SEEG) [NA]
This clinical trial is evaluating whether dynamic spectral imaging of cognitive functions can predict cognitive deficit risk after epilepsy …
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Computational Neuroscience of Language Processing in the Human Brain [NA]
A Massachusetts General Hospital-sponsored clinical trial is investigating computational neuroscience of language processing in the human br…
-
FDA approval · 2026-01-18FDA Approved: TOPIRAMATE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approves a supplemental application for TOPIRAMATE from Glenmark Pharmaceuticals Inc., USA.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application [NA]
The study investigates a self-administered, one-of-a-kind web-based music therapy for epilepsy. It is currently recruiting at Dartmouth-Hitc…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Predictive Value of Seizure Frequency at Onset for Long-Term Seizure Control
A clinical trial update from Assiut University assessing whether seizure frequency at onset can predict long-term seizure control in patient…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Human Intracranial Electrophysiology [NA]
A clinical trial titled 'Human Intracranial Electrophysiology' is currently recruiting for epilepsy.
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: MEG Versus EEG HR for the Localization of the Epileptogenic Zone as Part of the Pre-surgical Assessment of Epilepsy [NA]
This clinical trial compares magnetoencephalography (MEG) to high-resolution EEG for localizing the epileptogenic zone during pre-surgical a…
-
FDA approval · 2026-01-14FDA Approved: GABAPENTIN — Supplemental Application (Laurus Labs Limited)
FDA approved a supplemental application for gabapentin from Laurus Labs Limited (ANDA217965). This action approves the generic product for d…
-
CLINICAL_TRIALS other · 2026-01-14Clinical Trial Update: Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome [NA]
Clinical trial update describing a study on how epilepsy-related neurodevelopmental factors affect autonomic function in Dravet Syndrome. Th…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome [Phase 3]
A Phase 3 clinical trial is evaluating whether Levetiracetam can prevent seizures in adults with Down syndrome who have symptomatic Alzheime…
-
FDA approval · 2026-01-12FDA Approved: TOPIRAMATE — Original Application (Camber Pharmaceuticals, Inc.)
This FDA page confirms Camber Pharmaceuticals' original Abbreviated New Drug Application approval for a generic Topiramate product. The appr…